![\"Eli](\"https:\/\/www.newsbeep.com\/us-pa\/wp-content\/uploads\/2026\/01\/lilly_lehigh_valley_new_facility.jpg\")
(Source: Eli Lilly and Company)<\/p>\n(Source: Eli Lilly and Company)<\/p>\n
In what will be the largest single investment in Lehigh Valley history \u2014 and the largest life sciences project in Pennsylvania history \u2014 Eli Lilly and Company will invest $3.5 billion in a new pharmaceutical manufacturing facility. The site will serve as Lilly\u2019s newest injectable medicine and device manufacturing facility that will produce next-generation weight-loss therapies, including retatrutide, a first-in-class investigational GIP, GLP-1 and glucagon triple hormone receptor agonist. <\/p>\n
\u201cOur mission starts with patients and delivering the medicines they need,\u201d said David A. Ricks, Lilly chair and CEO. \u201cTo meet increasing demand, we\u2019re expanding our U.S. manufacturing network, with Lehigh Valley adding capacity for next\u2011generation weight-loss medicines. We\u2019re creating high\u2011quality jobs and collaborating across the region\u2014with suppliers, educators, and workforce\u2011development partners\u2014to make critical medicines in the U.S. That\u2019s our commitment\u2014to patients, to our new Pennsylvania home and to our country.\u201d<\/p>\n
In December, Lilly became the first drugmaker to reach $1 trillion in market value, buoyed by sales of weight loss and diabetes medications including Mounjaro and Zepbound. This is the fourth new U.S. manufacturing site Lilly has announced since February 2025, as part of its commitment to bolster domestic medicine production. <\/p>\n
Since 2020, Lilly\u2019s capital expansion commitments total more than $50 billion<\/a> and include:<\/p>\n New sites in Alabama<\/a>, Pennsylvania, Texas<\/a>, Virginia,<\/a> North Carolina<\/a> and Indiana<\/p>\n Development of the new Lilly Medicine Foundry in Indiana<\/a><\/p>\n Site expansions in Puerto Rico and at the Lilly Technology Center in Indianapolis<\/p>\n Acquisition and expansion of Lilly\u2019s manufacturing site in Wisconsin<\/a><\/p>\n Lilly Lands In Lehigh Valley<\/p>\n In Pennsylvania, Lilly will build 925,000 square feet over multiple buildings and create 850 new jobs over the next five years at the Fogelsville Corporate Center in Fogelsville. Construction is expected to begin in 2026, and the site will be operational in 2031.<\/p>\n The Lehigh Valley site was selected from more than 300 applications, partly based on its proximity to STEM universities, its technical manufacturing economy, and its existing infrastructure. In addition, with increasing demand from the biotech industry, the region offers convenient access to utilities, transportation, and favorable zoning and incentives.<\/p>\n \u201cLilly Lehigh Valley\u2014our newest injectable medicine and device manufacturing facility\u2014will increase access to next-generation weight-loss treatments and improve the domestic supply of essential medicines for current and future patients,\u201d said Edgardo Hernandez, executive vice president and president of Lilly Manufacturing Operations. \u201cOur investment here is more than just building a facility\u2014it\u2019s about building a shared future with the people and communities of the Commonwealth. Through meaningful partnerships in Pennsylvania, we\u2019re committed to fostering collaboration, driving innovation, advancing environmental stewardship, and creating lasting positive impact that extends far beyond our facility walls.\u201d<\/p>\n The Pennsylvania Department of Community & Economic Development <\/a>has committed more than $100 million to the project: $50 million in tax credits through the PA Edge Tax Credit Program, a $25 million grant through the PA SITES (Pennsylvania Strategic Investments to Enhance Sites) Program, and a $25 million Pennsylvania First grant.\u00a0<\/p>\n \u201cLilly\u2019s commitment to the Lehigh Valley and to Pennsylvania will bring billions of dollars of investment and hundreds of good-paying jobs, solidifying our position as a leader in the growing life sciences industry,\u201d said Governor Josh Shapiro.\u00a0<\/p>\n The Lehigh Valley Economic Development Corporation (LVEDC)<\/a> played a key role in Lilly\u2019s competitive site selection process, coordinating with state officials and convening local and regional partners to put together a plan to meet the company\u2019s infrastructure, utility, and workforce needs and ensure that the project can be completed on time.<\/p>\n \u201cToday, Eli Lilly and Company write the first page of a new chapter \u2013 the era of life sciences \u2013 in the Lehigh Valley\u2019s proud history of making things in America,\u201d said Don Cunningham, LVEDC President & CEO .<\/p>\n The development of the Lilly site will occur through the state\u2019s PA Permit Fast Track Program<\/a>, which helps develop, manage, and coordinate permitting for complex and impactful economic development and infrastructure projects. The project was coordinated at the state level by Gov. Shapiro\u2019s BusinessPA team and involved top level officials including Pennsylvania Secretary of Community and Economic Development Rick Siger and Chief Transformation and Opportunity Officer Ben Kirshner.<\/p>\n